Figure 1.Dose-dependent effects of fisetin on calcific marker expression in VSMCs during pro-calcific conditions. Relative mRNA expression (n=12) of BMP2 (A) and ALPL (B) in HAoSMCs treated for 48h with control (CTR) or calcification medium (Calc.) without and with the indicated concentrations of fisetin (Fis, 0 - 20 μM). **(p<0.01), ***(p<0.001) significant vs. control group; †(p<0.05), ††(p<0.01) significant vs. Calc.-treated group.
